LT2948777T - Baltymai su pasikartojančiais dipeptidais, kaip terapinis taikinys neurodegeneracinių ligų su padidėjusiu heksanukleotidų pasikartojimu atveju - Google Patents
Baltymai su pasikartojančiais dipeptidais, kaip terapinis taikinys neurodegeneracinių ligų su padidėjusiu heksanukleotidų pasikartojimu atvejuInfo
- Publication number
- LT2948777T LT2948777T LTEP14701089.6T LT14701089T LT2948777T LT 2948777 T LT2948777 T LT 2948777T LT 14701089 T LT14701089 T LT 14701089T LT 2948777 T LT2948777 T LT 2948777T
- Authority
- LT
- Lithuania
- Prior art keywords
- repeat
- dipeptide
- neurodegenerative diseases
- therapeutic target
- hexanucleotide
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/000190 WO2014114303A1 (en) | 2013-01-22 | 2013-01-22 | Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion |
| EP13185419 | 2013-09-20 | ||
| PCT/EP2014/051204 WO2014114660A1 (en) | 2013-01-22 | 2014-01-22 | Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2948777T true LT2948777T (lt) | 2019-09-25 |
Family
ID=49999965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14701089.6T LT2948777T (lt) | 2013-01-22 | 2014-01-22 | Baltymai su pasikartojančiais dipeptidais, kaip terapinis taikinys neurodegeneracinių ligų su padidėjusiu heksanukleotidų pasikartojimu atveju |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10066007B2 (lt) |
| EP (2) | EP3588091A1 (lt) |
| CY (1) | CY1122079T1 (lt) |
| DK (1) | DK2948777T3 (lt) |
| ES (1) | ES2744804T3 (lt) |
| HR (1) | HRP20191608T1 (lt) |
| HU (1) | HUE046434T2 (lt) |
| LT (1) | LT2948777T (lt) |
| PL (1) | PL2948777T3 (lt) |
| PT (1) | PT2948777T (lt) |
| RS (1) | RS59283B1 (lt) |
| SI (1) | SI2948777T1 (lt) |
| SM (1) | SMT201900507T1 (lt) |
| WO (1) | WO2014114660A1 (lt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014062691A2 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | METHOD FOR MONITORING THE C9ORF72 EXPRESSION |
| DK2906696T4 (da) | 2012-10-15 | 2023-02-27 | Ionis Pharmaceuticals Inc | Fremgangsmåder til modulering af c9orf72-ekspression |
| HUE046434T2 (hu) * | 2013-01-22 | 2020-03-30 | Deutsches Zentrum Fuer Neurodegenerative Erkrankungen E V | Dipeptid-ismétlõdõ fehérjék terápiás célpontként neurodegeneratív betegségekben, hexanukleotid ismétlõdõ expanzióval |
| EP2948471A4 (en) | 2013-01-24 | 2016-08-10 | Mayo Foundation | METHOD AND MATERIALS FOR DETECTING POSITIVE FRONTOTEMPORAL PAPER DEGENERATION BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION OR AMYOTROPHATE LATERAL SCLEROSIS BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION |
| HK1220227A1 (zh) | 2013-03-14 | 2017-04-28 | University Of Florida Research Foundation, Inc. | 与als有关的重复含有蛋白质的二氨基酸 |
| EP3055414A4 (en) | 2013-10-11 | 2017-07-19 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| NZ729808A (en) * | 2014-09-30 | 2022-02-25 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
| MY181815A (en) * | 2015-04-16 | 2021-01-08 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
| US10509045B2 (en) | 2015-05-29 | 2019-12-17 | University Of Florida Research Foundation, Incorporated | Methods for diagnosing Huntington's disease |
| US11260073B2 (en) | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
| AU2017246643B2 (en) | 2016-04-04 | 2022-08-04 | University Of Florida Research Foundation, Incorporated | Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation |
| US11345911B2 (en) | 2017-04-17 | 2022-05-31 | University Of Florida Research Foundation, Incorporated | Regulation of RAN translation by PKR and eIF2A-P pathways |
| JP6959632B2 (ja) * | 2017-05-15 | 2021-11-02 | 学校法人近畿大学 | 筋萎縮性側索硬化症又は前頭側頭型認知症の予防又は治療剤 |
| EP3688021A4 (en) | 2017-09-26 | 2021-12-29 | University of Florida Research Foundation, Incorporated | Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders |
| CA3097872A1 (en) | 2018-04-27 | 2019-10-31 | Biogen Ma Inc. | Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody |
| CN108795935B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 1基因的siRNA及其应用 |
| TWI781347B (zh) * | 2018-10-01 | 2022-10-21 | 美商Ｕｎｓ Ｉｐ控股公司 | 針對源自c9orf72二肽重複蛋白的胜肽免疫原結構 |
| US20220202935A1 (en) * | 2019-05-02 | 2022-06-30 | Deutsches Zentrum Für Neurodegenrative Erkrankungen E.V.(Dzne) | Immunogen for Preventing or Treating Familial Frontotemporal Dementia (FTD) and/or Amyotrophic Lateral Sclerosis (ALS) |
| EP3994159A4 (en) * | 2019-07-05 | 2023-08-09 | University of Florida Research Foundation, Incorporated | METHODS OF TREATING NEUROLOGICAL DISEASES ASSOCIATED WITH THE RAN PROTEIN |
| EP4031562A4 (en) * | 2019-09-20 | 2023-11-01 | University of Florida Research Foundation, Incorporated | DETECTION OF ANTIBODIES AGAINST RAN PROTEINS FROM SERUM AND TISSUE LYSATES |
| EP4034550A4 (en) * | 2019-09-23 | 2023-09-27 | University of Florida Research Foundation, Incorporated | VACCINE THERAPY FOR RAN PROTEIN DISEASES |
| CA3259546A1 (en) * | 2022-06-13 | 2023-12-21 | Yeefan Med Inc | METHODS FOR DETECTING B-ISOX PRECIPITIES OR CAPTURED PROTEINS AS BIOMARKERS OF BIOFLUID |
| WO2024097756A1 (en) * | 2022-11-01 | 2024-05-10 | University Of Florida Research Foundation, Incorporated | Interrupted ran proteins in disease |
| EP4615415A1 (en) * | 2022-11-11 | 2025-09-17 | Mayo Foundation for Medical Education and Research | Treating proteinopathies |
| WO2024229355A1 (en) * | 2023-05-04 | 2024-11-07 | The Johns Hopkins University | Methods for decreasing neuronal death, inflammation, and degeneration |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030143668A1 (en) * | 2001-06-18 | 2003-07-31 | National Institute Of Advanced Industrial | Guanosine triphosphate-binding protein coupled receptors |
| US20040102608A1 (en) * | 2002-05-13 | 2004-05-27 | Cornell Research Foundation, Inc. | Multiblock copolymers having improved mechanical properties |
| WO2005103235A1 (ja) * | 2004-04-19 | 2005-11-03 | Denka Seiken Co., Ltd. | ウイルスの生産方法 |
| US8148111B2 (en) * | 2006-03-17 | 2012-04-03 | Sanyo Chemical Industries, Ltd. | Cell culture carrier comprising poly(meth)acrylic (salt) particle and artificial polypeptide |
| US20130115603A9 (en) | 2009-04-02 | 2013-05-09 | Regents Of The University Of Minnesota | Nucleotide repeat expansion-associated polypeptides and uses thereof |
| SI2571510T1 (sl) | 2010-05-21 | 2019-02-28 | Xl-Protein Gmbh | Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe |
| WO2014062691A2 (en) * | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| HUE046434T2 (hu) * | 2013-01-22 | 2020-03-30 | Deutsches Zentrum Fuer Neurodegenerative Erkrankungen E V | Dipeptid-ismétlõdõ fehérjék terápiás célpontként neurodegeneratív betegségekben, hexanukleotid ismétlõdõ expanzióval |
-
2014
- 2014-01-22 HU HUE14701089A patent/HUE046434T2/hu unknown
- 2014-01-22 PT PT14701089T patent/PT2948777T/pt unknown
- 2014-01-22 US US14/762,623 patent/US10066007B2/en active Active
- 2014-01-22 EP EP19180100.0A patent/EP3588091A1/en active Pending
- 2014-01-22 WO PCT/EP2014/051204 patent/WO2014114660A1/en not_active Ceased
- 2014-01-22 HR HRP20191608 patent/HRP20191608T1/hr unknown
- 2014-01-22 EP EP14701089.6A patent/EP2948777B1/en active Active
- 2014-01-22 DK DK14701089.6T patent/DK2948777T3/da active
- 2014-01-22 SI SI201431324T patent/SI2948777T1/sl unknown
- 2014-01-22 SM SM20190507T patent/SMT201900507T1/it unknown
- 2014-01-22 RS RSP20191145 patent/RS59283B1/sr unknown
- 2014-01-22 LT LTEP14701089.6T patent/LT2948777T/lt unknown
- 2014-01-22 PL PL14701089T patent/PL2948777T3/pl unknown
- 2014-01-22 ES ES14701089T patent/ES2744804T3/es active Active
-
2019
- 2019-09-05 CY CY20191100935T patent/CY1122079T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10066007B2 (en) | 2018-09-04 |
| DK2948777T3 (da) | 2019-09-23 |
| HRP20191608T1 (hr) | 2019-12-13 |
| CY1122079T1 (el) | 2020-11-25 |
| ES2744804T3 (es) | 2020-02-26 |
| HUE046434T2 (hu) | 2020-03-30 |
| US20150361166A1 (en) | 2015-12-17 |
| WO2014114660A1 (en) | 2014-07-31 |
| EP2948777A1 (en) | 2015-12-02 |
| PT2948777T (pt) | 2019-09-26 |
| RS59283B1 (sr) | 2019-10-31 |
| EP3588091A1 (en) | 2020-01-01 |
| SMT201900507T1 (it) | 2019-11-13 |
| EP2948777B1 (en) | 2019-06-26 |
| PL2948777T3 (pl) | 2019-12-31 |
| SI2948777T1 (sl) | 2019-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2948777T1 (sl) | Dipeptidno ponavljajoči se proteini kot terapevtski cilj pri nevrodegenerativnih boleznih s ponavljajočo ekspanzijo heksanukleotida | |
| IL245744A0 (en) | Therapeutic peptides | |
| LT3041864T (lt) | Il-18 surišantis baltymas (il-18p) uždegiminių ligų atvejais | |
| SG10202011130TA (en) | Continuous purification of therapeutic proteins | |
| SG11201506766PA (en) | Therapeutic peptides | |
| SG11201508469YA (en) | Therapeutic peptides | |
| ZA201600086B (en) | Therapeutic fusion protein | |
| SG10201709090UA (en) | Sobetirome in the treatment of myelination diseases | |
| SG11201505198WA (en) | Protein purification methods | |
| SG11201603028SA (en) | Purification of proteins | |
| SG11201505204VA (en) | Protein purification process | |
| GB2541582B (en) | Hint based spot healing techniques | |
| GB201308057D0 (en) | Protein | |
| GB201304973D0 (en) | Recombinant protein | |
| IL240639A0 (en) | Formulations and methods for increased recombinant production of protein | |
| SG11201509450QA (en) | Methods to produce particles comprising therapeutic proteins | |
| GB201401955D0 (en) | Protein | |
| EP2978770A4 (en) | REINFORCEMENT OF PROTEINS | |
| GB201309967D0 (en) | Therapeutic combinations | |
| GB201320209D0 (en) | Improvements in or relating to protein Micro-nets | |
| GB201804143D0 (en) | Human target II | |
| GB201302030D0 (en) | Protein | |
| GB201302031D0 (en) | Protein | |
| GB201301072D0 (en) | Therapeutic Moisturiser | |
| GB201300778D0 (en) | Therapeutic moisturiser |